{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-007347","form_type":"8-K","ticker":"ENVB","cik":"0000890821","company_name":"Enveric Biosciences, Inc.","filed_at":"2024-02-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.190998+00:00","generated_at":"2026-06-05T22:33:42.134027+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"ENVB unveils library of 57+ preclinical compounds targeting mental health disorders","bullets":["Library spans 7 molecule classes including SNDRIs, NSRIs, MDMA derivatives, psilocin prodrugs, and melatonin agonists.","Compounds are protected by Enveric's IP portfolio and represent potential out-licensing and non-dilutive revenue streams.","Lead candidates EB-003 (non-hallucinogenic neuroplastogen) and EB-002 (psilocin prodrug) remain focus; library adds depth.","Novel MDMA derivatives show varying 5-HT2A binding; some designed to reduce hallucinogenic potential while retaining neuroplasticity."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-007347","json":"https://secwatch.observer/filing/0001493152-24-007347.json","markdown":"https://secwatch.observer/filing/0001493152-24-007347.md","text":"https://secwatch.observer/filing/0001493152-24-007347.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/890821/000149315224007347/0001493152-24-007347-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/890821/000149315224007347/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T22:33:42.134027+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}